Skin News and Research

RSS

The Wistar Institute Melanoma Research Center launched to develop new therapies for melanoma

In an effort to meet the rising rates of melanoma head-on, The Wistar Institute today announced the creation of The Wistar Institute Melanoma Research Center. The Center brings together scientists, physicians, the life sciences industry, and melanoma advocates in saving lives by advancing new and better therapies for this deadly disease.

28 May 2010

CDP-choline may block skull and brain damage that result from alcohol consumption early in pregnancy

The dietary supplement CDP-choline, sold as a brain-boosting agent and under study for stroke and traumatic brain injury, may block skull and brain damage that can result from alcohol consumption early in pregnancy, Medical College of Georgia researchers report.

28 May 2010

PCA-Rx represents next generation of chelation technology for ASD patients

According to the Center for Disease Control, autism has risen to an epidemic rate of 1 in 100 in the U.S., up from 1 in 150 in 2007. While controversy looms regarding its cause, many parents of autistic children believe a correlation exists with toxin accumulation. To give autism spectrum disorder sufferers a natural alternative to chelation therapy, Maxam Nutraceutics has introduced PCA-Rx.

28 May 2010

Scientists develop inexpensive method for determining chemicals that may cause skin allergies

Scientists are reporting development of a fast, simple, inexpensive method for determining whether chemicals in consumer products and workplaces may cause skin allergies in people -- a method that does not involve use of animals. Their study appears in ACS' Chemical Research in Toxicology, a monthly journal.

27 May 2010

Leading stem cell scientists to discuss on stem cell clinical trials for ALS and heart attack patients

The first Cedars-Sinai Regenerative Medicine Scientific Symposium, dedicated to furthering our ability to bring stem cell therapies from the laboratory to the patient bedside. The conference, led by Clive Svendsen, Ph.D., and Eduardo Marb-n, M.D., Ph.D., will highlight the most recent developments in leading-edge stem cell research and treatments for brain and heart diseases.

27 May 2010

Physicians diagnose rare parasitic infection in people who consumed raw crayfish

If you're headed to a freshwater stream this summer and a friend dares you to eat a raw crayfish - don't do it. You could end up in the hospital with a severe parasitic infection.

27 May 2010

FDA advises consumers, health care professionals about Xenical, Alli

The U.S. Food and Drug Administration today advised consumers and health care professionals about potential rare occurrences of severe liver injury in patients taking the weight-loss medication orlistat, marketed as Xenical and Alli.

27 May 2010

Nottingham scientists given green light to test new vaccine for malignant melanoma

Nottingham scientists have been given the green light to test a vaccine which they hope could reverse, and even cure malignant melanoma, the most deadly type of skin cancer.

27 May 2010

GSK Consumer Healthcare announces update of alli product label

GSK Consumer Healthcare today announced it will update the alli product label to alert consumers to certain symptoms that have been associated with rare instances of severe liver injury reported in people taking orlistat, the active ingredient in alli. This update follows FDA's completion of its safety review of orlistat and is being implemented in conjunction with Roche, the manufacturer of the prescription dose of orlistat (Xenical). The agency stated that a cause and effect relationship has not been established.

27 May 2010

National Council on Skin Cancer Prevention introduces Don't Fry Day to encourage sun safety awareness

As millions of Americans prepare to enjoy the great outdoors Memorial Day weekend, the National Council on Skin Cancer Prevention reminds everyone to practice sun-safe behaviors – pack those wide-brimmed hats in the suitcase. The incidence of melanoma (the most fatal of skin cancers) continues to rise significantly, at a rate faster than any of the seven most common cancers.

26 May 2010

Ambrotose AO capsules raise antioxidant protection in serum ORAC in healthy adults: Study

Mannatech, Incorporated, a global pioneer in the development of high-quality health, weight and fitness, and skin care solutions based on nutritional science, announced the results of an independent human clinical study that demonstrated intake of its proprietary Ambrotose AO capsules raised antioxidant protection in serum oxygen radical absorbance capacity in healthy adults, further validating a previous human study.

26 May 2010

Highlights from June 2010 issue of American Journal of Pathology

Dr. Kanneboyina Nagaraju and colleagues at the Children's National Medical Center, Washington, DC demonstrate that affected muscle may directly contribute to inflammation in muscular dystrophy. Their report can be found in the June 2010 issue of The American Journal of Pathology.

26 May 2010

Consequences of secrecy in medicine

No one knows how many mothers' and babies' lives have been saved by the obstetrical forceps. This device has been part of the standard equipment of every maternity room for about 250 years. However, a shadow lies over the success story: after the Chamberlen brothers developed the device at the beginning of the 17th century, the brothers and their descendants used it for 3 generations, but kept it a secret from other obstetricians.

26 May 2010

RCSI researchers identify biomarker that can predict severity of breast cancer

Researchers from the Royal College of Surgeons in Ireland have identified a biomarker in patient blood which can predict the severity of breast cancer in patients and may enable clinicians to track patients throughout the course of their treatment.

26 May 2010

Lumizyme receives FDA approval for patients with late-onset Pompe disease

The U.S. Food and Drug Administration approved Lumizyme (alglucosidase alfa) for patients ages 8 years and older with late-onset (non-infantile) Pompe disease, a rare genetic disorder.

26 May 2010

Valocor Therapeutics acquires, licenses dermatology therapeutic programs from QLT

Valocor Therapeutics, Inc., a newly formed company focused on the development of innovative therapies for the treatment of dermatologic conditions, today announced the acquisition and license of certain dermatology therapeutic programs from QLT Inc.. This transaction was facilitated by a seed financing for Valocor led by the Working Opportunity Fund, which is managed by GrowthWorks Capital Ltd.

25 May 2010

Consumer Reports Health rates four spray-on sunscreens

Memo to beach bums: get ready to pump it and spray it, and don't apply it in the wind. New tests of sunscreens by Consumer Reports Health reveal that four spray-on sunscreens provided the best protection from the sun's Ultraviolet A (UVA) and Ultraviolet B (UVB) rays. The ratings are available in the July issue of the magazine. The magazine also looks at insect repellents. Both articles are available in Spanish on www.consumerreportsenespanol.org.

25 May 2010

NovaBay Pharmaceuticals completes enrollment in Phase 2a trial of NVC-422 for treatment of impetigo

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, today announced the completion of enrollment in a Phase 2a proof-of-concept trial for the treatment of impetigo.

25 May 2010

Family of EPA-registered disinfecting products to be launched

An innovative family of EPA-registered disinfecting products will be launched through a new direct selling company, it was announced today.

25 May 2010

Preclinical results of AMEP for metastatic melanoma presented at ASGCT Annual Meeting

BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, has presented efficacy, safety and biodistribution results on its new biotherapy AMEP™ for advanced and metastatic melanoma at the 13th Annual Meeting of the American Society of Gene and Cell Therapy in Washington, DC (May 17 - 22, 2010).

25 May 2010

Skin News and Research

The Wistar Institute Melanoma Research Center launched to develop new therapies for melanoma

CDP-choline may block skull and brain damage that result from alcohol consumption early in pregnancy

PCA-Rx represents next generation of chelation technology for ASD patients

Scientists develop inexpensive method for determining chemicals that may cause skin allergies

Leading stem cell scientists to discuss on stem cell clinical trials for ALS and heart attack patients

Physicians diagnose rare parasitic infection in people who consumed raw crayfish

FDA advises consumers, health care professionals about Xenical, Alli

Nottingham scientists given green light to test new vaccine for malignant melanoma

GSK Consumer Healthcare announces update of alli product label

National Council on Skin Cancer Prevention introduces Don't Fry Day to encourage sun safety awareness

Ambrotose AO capsules raise antioxidant protection in serum ORAC in healthy adults: Study

Highlights from June 2010 issue of American Journal of Pathology

Consequences of secrecy in medicine

RCSI researchers identify biomarker that can predict severity of breast cancer

Lumizyme receives FDA approval for patients with late-onset Pompe disease

Valocor Therapeutics acquires, licenses dermatology therapeutic programs from QLT

Consumer Reports Health rates four spray-on sunscreens

NovaBay Pharmaceuticals completes enrollment in Phase 2a trial of NVC-422 for treatment of impetigo

Family of EPA-registered disinfecting products to be launched

Preclinical results of AMEP for metastatic melanoma presented at ASGCT Annual Meeting

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News